stock-detail (BDSI)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/24/2017 12:17 pm

4/24/2017 12:17 pm

4/24/2017 12:17 pm

4/24/2017 12:17 pm

4/24/2017 12:17 pm

4/18/2017 12:17 am

4/18/2017 12:17 am

4/18/2017 12:17 am

4/18/2017 12:17 am

4/18/2017 12:17 am

Blog Coverage BioDelivery Extends its Patent Portfolio; Acquires Extended Patents for BELBUCA, BUNAVIL, and ONSOLIS

4/3/2017 12:01 pm

[Accesswire] - Upcoming AWS Coverage on Corbus Pharmaceuticals Holdings Post-Earnings Results LONDON, UK / ACCESSWIRE / April 3, 2017 / Active Wall St. blog coverage looks at the headline from Biodelivery Sciences International, ...

BioDelivery Sciences Announces the Granting of Two New Patents to be Listed in FDA's Orange Book Further Extending and Strengthening Patent Protection on BELBUCA®, BUNAVAIL® and ONSOLIS®

3/31/2017 11:00 am

[PR Newswire] - RALEIGH, N.C., March 31, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that two important new patents were granted extending patent protection around all three ...

BioDelivery Sciences International and Rexahn Pharmaceuticals See Share Values Rise Slightly

3/28/2017 01:03 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 28, 2017 / These two stocks posted gains on Monday as they are likely to reduce losses going ahead. Both companies also moved forward with the FDA trials as their lead ...

BioDelivery reports 4Q loss

3/17/2017 10:04 am